

REMARKS

Status of the Claims

Claims 1, 5, 7-18, 22-25, 27, 31-33, 35, 37, 41, and 43-48 were pending. Claim 41 has been canceled. Claim 37 has been amended. New claims 49-54 were added.. No new matter has been added.

Claim Amendments

Claim 37 has been amended to recite "wherein said first polypeptide is linked to said second polypeptide by at least one amino acid." Support for this amendment can be found throughout the application but at least at page 8 lines 4-6 of the application as filed.

New claim 49 has been added. Support for this claim can be found throughout the application and at least at page 10 lines 31-32 and page 12 lines 1-8 of the application as filed.

New claim 50 has been added. Support for this claim can be found throughout the application and at least at page 8 lines 6-11 of the application as filed.

New claim 51 has been added. Support for this claim can be found throughout the application and at least at page 8 lines 11-16, and page 10 lines 21-26 of the application as filed.

New claim 52 has been added. Support for this claim can be found throughout the application and at least at page 9 lines 1-7 of the application as filed.

New claim 53 has been added. Support for this claim can be found throughout the application and at least at page 9 lines 8-33 of the application as filed.

New claim 54 has been added. Support for this claim can be found throughout the application and at least at page 8 lines 4-6, and page 9 lines 8-15 of the application as filed.

Restriction

The Action imposed a 5-way restriction requirement as follows: Group I, claims 1, 5, 7, 8-15, 31 and 33, are drawn to chimeric L1 and L2 and second protein and method of inducing immune response; Group II, claims 1, 16, 17, 18, 22-25, 32 and 35 are drawn to capsomere complex, and method of inducing immune response utilizing the complex; Group III, claim 27, is drawn to nucleic acid; Group IV, claims 37, 41, and 43-45, are drawn to chimeric protein of papillomavirus L1 and second protein; and Group V, claims 46-48, are drawn to method of inducing immune response against a peptide.

The Applicants provisionally elect Group IV, claims 37 and 43-45. In addition,

Appln. No.: 10/541,895
66888.319995
CU2002.095H

Applicants respectfully request the addition of new claims 49-54 to the election of Group IV.

Applicants reserve the right pursuant to 35 U.S.C. §121 to file one or more divisional, continuation or continuation-in-part applications directed to the non-elected claims and unclaimed subject matter during the pendency of the instant application.

CONCLUSION

For the reasons stated above, Applicants assert that the response is in compliance with response to the outstanding restriction and requests review of at least claims 37, 43-45 and new claims 49-54 at this time. Please feel free to call the undersigned, if additional response is required.

Respectfully submitted,

FAEGRE & BENSON LLP

By: /Roberta Jean Hanson/

Roberta Jean Hanson

Reg. No. 51,774

(303) 607-3766

Customer No.: 35657

Dated: April 18, 2008

Response to Restriction Requirement.dot